Startseite
Kongressberichte 2019
Annual Meeting of the American Society of Clinical Oncology 2019
Press Briefings
Press Briefing Sunday June 2:
Sunday June 2 Press Briefing: ASCO Press Releases with links to abstracts
(Webcasts at the bottom of page)
Earlier Ovarian Cancer Diagnoses and Treatment Seen After ACA Implementation
|
Conclusions: Under the Affordable Care Act, women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis. As stage and treatment are major determinants of survival, these gains under the ACA may have long-term impacts on women with ovarian cancer. |
CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT
Private Insurance, Higher Regional Incomes, and Certain Practice Settings Predict Longer Survival for People With Multiple Myeloma
CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT
Conclusions: Insurance type and regional income are associated with MM survival. This may be related to affordability of OAM and merits further investigation.
| HR | 95% CI | p | |
|---|---|---|---|
| Age per year increase | 1.04 | 1.04 - 1.05 | < .0001 |
| Male/female | 1.06 | .99 - 1.14 | .098 |
| White/black | 1.07 | .98 - 1.17 | .124 |
| Primary/secondary MM | .95 | .86 - 1.04 | .242 |
| CCI 0/≥3 | .48 | .39 - .59 | < .0001 |
| 1/≥3 | .7 | .57 - .87 | .002 |
| 2/≥3 | .92 | .72 - 1.16 | .47 |
| Academic institution/other | 1.49 | 1.39 - 1.59 | < .0001 |
| Medicare/private insurance | 1.09 | .99 - 1.2 | .073 |
| Medicaid/private insurance | 1.59 | 1.36 - 1.87 | < .0001 |
| Not insured/private insurance | 1.62 | 1.32 - 1.99 | < .0001 |
| Other/private insurance | .95 | .66 - 1.39 | .802 |
| Median income in area of residence < $46k/≥ $46k | 1.16 | 1.08 - 1.25 | < .0001 |
* Stem cell transplant status not included (only 15.7% were reported to have received it).
Racial Disparities in Access to Timely Cancer Treatment Nearly Eliminated in States With Medicaid Expansion
Conclusions:Implementation of Medicaid expansions as part of the ACA differentially improved African American cancer pts’ receipt of timely treatment, reducing racial disparities in access to care.
| Pre-Expansion | Post-Expansion | Pre-Post Change | |
|---|---|---|---|
| White | 41.8 | 43.1 | 1.8 |
| African American | 39.1 | 44.3 | 6.9** |
| Adjusted disparity (African American vs whites) | -4.9** | 0.2 | 5.1** |
** p < 0.05
CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT
Adding Enzalutamide to Standard First-Line Treatment Improves Survival for Men With Metastatic Hormone-Sensitive Prostate Cancer
Conclusions: ENZA significantly improved OS when added to SOC in mHSPC. The benefits appeared lower in those planned to receive early DOC. Results of analyses with updated follow-up triggered by this IA will be presented. Clinical trial information: NCT02446405
| Group [N] | HR (95% CI) | NSAA 3yOS% |
ENZA 3yOS% |
|---|---|---|---|
| All pts [1125] | 0.66 (0.51-0.86), p = 0.0016 | 72 | 79 |
| High volume disease [596] | 0.74 (0.55-1.01) | 63 | 71 |
| Low volume disease [529] | 0.48 (0.28-0.80) | 82 | 89 |
| No planned early DOC [622] | 0.51 (0.36 to 0.73) | 70 | 83 |
| Planned early DOC [503] | 0.91 (0.62 to 1.35) | 74 | 73 |
CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT
The following articles were published on NEJM.org to coincide with a meeting of the American Society of Clinical Oncology.
ORIGINAL ARTICLE
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
I.D. Davis and Others
Maintenance Therapy With PARP Inhibitor Olaparib Delays Progression of BRCA-Related Pancreatic Cancer
Conclusions: Maintenance olaparib provided a statistically significant and clinically meaningful improvement in PFS in mPC pts with a gBRCAm who had not progressed on PBC. Safety was consistent with the known profile for olaparib. POLO is the first phase III trial to validate a biomarker-driven treatment in PC. Clinical trial information: NCT02184195
| Time, mo |
O N = 92, % |
P N = 62, % |
|---|---|---|
| 6 | 53.0 | 23.0 |
| 12 | 33.7 | 14.5 |
| 18 | 27.6 | 9.6 |
| 24 | 22.1 | 9.6 |
*Kaplan-Meier method
CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT
The following articles were published on NEJM.org to coincide with a meeting of the American Society of Clinical Oncology.
ORIGINAL ARTICLE
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
T. Golan and Others